Englander Institute for Precision Medicine

Publications

Found 23 results
Author Title Type [ Year(Asc)]
Filters: Author is Barbieri, Christopher E  [Clear All Filters]
2023
Benedetti E, Chetnik K, Flynn T, Barbieri CE, Scherr DS, Loda M, Krumsiek J.  2023.  Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort.. Sci Data. 10(1):830.
Marciscano AE, Wolfe S, Zhou XKathy, Barbieri CE, Formenti SC, Hu JC, Molina AM, Nanus DM, Nauseef JT, Scherr DS et al..  2023.  Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).. BMC Cancer. 23(1):781.
Geng C, Zhang M-C, Manyam GC, Vykoukal JV, Fahrmann JF, Peng S, Wu C, Park S, Kondraganti S, Wang D et al..  2023.  SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.. Clin Cancer Res. 29(21):4464-4478.
2022
Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M et al..  2022.  Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.. JCI Insight. 7(4)
Deshpande AS, Ulahannan N, Pendleton M, Dai X, Ly L, Behr JM, Schwenk S, Liao W, Augello MA, Tyer C et al..  2022.  Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing.. Nat Biotechnol. 40(10):1488-1499.
Cai PY, Asad M, Augello MA, Martin L, Louie C, Basourakos SP, Gaffney CD, Shoag J, Tu JJenny, Khani F et al..  2022.  A multidisciplinary approach to optimize primary prostate cancer biobanking.. Urol Oncol. 40(6):271.e1-271.e7.
2021
Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, Deonarine LDayal, Cyrta J, Davicioni E, Sboner A et al..  2021.  G3BP1 inhibits Cul3 to amplify AR signaling and promote prostate cancer.. Nat Commun. 12(1):6662.
Grbesa I, Augello MA, Liu D, McNally DR, Gaffney CD, Huang D, Lin K, Ivenitsky D, Goueli R, Robinson BD et al..  2021.  Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity.. Cell Rep. 36(10):109625.
Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, R Karnes J, Trock BJ, Klein EA, Den RB et al..  2021.  Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.. J Clin Invest. 131(10)
2020
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y et al..  2020.  Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.. Nature. 585(7826):E20.
Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, Vosoughi A, Fontugne J, Pan H, Lee D et al..  2020.  Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.. Nat Commun. 11(1):1987.
2019
Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y et al..  2019.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.. Cancer Cell. 35(4):603-617.e8.
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y et al..  2019.  FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.. Nature. 571(7765):408-412.
Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, G Han C, Coleman I et al..  2019.  Publisher Correction: The long tail of oncogenic drivers in prostate cancer.. Nat Genet. 51(7):1194.
2018
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, G Han C, Coleman I et al..  2018.  The long tail of oncogenic drivers in prostate cancer.. Nat Genet. 50(5):645-651.
Arora K, Barbieri CE.  2018.  Molecular Subtypes of Prostate Cancer.. Curr Oncol Rep. 20(8):58.
Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L, Robinson BD, Mosquera JMiguel, Chen Y, Rubin MA et al..  2018.  SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.. J Clin Invest. 128(1):381-386.
Boysen G, Rodrigues DN, Rescigno P, Seed G, Dolling D, Riisnaes R, Crespo M, Zafeiriou Z, Sumanasuriya S, Bianchini D et al..  2018.  SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.. Clin Cancer Res. 24(22):5585-5593.
2017
Dutta A, Panja S, Virk RK, Kim JYeji, Zott R, Cremers S, Golombos DM, Liu D, Mosquera JMiguel, Mostaghel EA et al..  2017.  Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.. Eur Urol. 72(4):499-506.
Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.  2017.  DNA Repair in Prostate Cancer: Biology and Clinical Implications.. Eur Urol. 71(3):417-425.
Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA.  2017.  The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.. Eur Urol. 71(2):237-246.
Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, Nataraj S, Deonarine LD, Augello MA, Sailer V et al..  2017.  SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.. Cancer Cell. 31(3):436-451.